N/A N=17 Randomized Treatment

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

Hypertension · Plasma Renin Activity

Bottom Line

View on ClinicalTrials.gov: NCT01658657 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2015

Primary outcome: Primary: Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic — 3; 1 participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Hydrochlorothiazide (Drug); Lisinopril (Drug); Amlodipine (Drug); metoprolol (Drug); lisinopril/hydrochlorothiazide (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of North Carolina, Chapel Hill
Primary completion: Jul 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Blood Pressure Control, as Defined as Office BP Measurement of <140 mmHg Systolic and <90 mmHg Diastolic	3; 1	—

Summary

The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment. Plasma renin is an enzyme in your blood that can be measured to determine your hypertension subtype. Once the subtype is known, doctors can prescribe specific medications to target your specific hypertension subtype. This study will investigate whether targeting the specific hypertension subtype helps to achieve blood pressure control sooner and with fewer medications compared to a standard fixed dose combination therapy.

Eligibility Criteria

Inclusion Criteria

Systolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 150 mmHg, or diastolic BP average during at least one recent (within 1 month) clinic or emergency room visit ≥ 95 mmHg
Not currently taking BP-lowering medication
Clinician recommends pharmacologic treatment
Willing to make necessary study visits
Able to be contacted by phone
Has a primary care clinician
At least 18 years old

Exclusion Criteria

Known secondary cause of hypertension
Pregnancy
Known diabetes, coronary artery disease or renal disease
Known sulfonamide allergy or history of gout
Participant's clinician recommends he/she not enroll
Hyponatremia, hypokalemia, hypernatremia, or hyperglycemia at baseline visit
Baseline visit systolic visit BP average < 140 mmHg and diastolic BP average < 90 mm Hg
Resting heart rate < 55 beats per minute

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01658657). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.